Novo raises outlook on continued demand for Wegovy pill and Ozempic
FROM THE WIRE · SEEKINGALPHA.COM
[New Nordisk] hapabapa/iStock Editorial via Getty Images Novo (NVO [https://seekingalpha.com/symbol/NVO]) raised its outlook for the year once again, driven by continued demand for its Wegovy weight-loss pill, and its older shot Ozempic. The Danish drugmaker now expects sales…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA guidance raise from a major drugmaker in the GLP-1 segment can move the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novo now expects sales and operating profit to decline 2% or rise up to 2%.
- 02Third-quarter net sales reached DKK 79.19 billion, up 6% year over year.
- 03Adjusted operating profit rose 34%, beating analyst estimates.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Novo Nordisk A/S40.19 USDMarket closedtoday -0.64%Positive Eli Lilly and Company1,409.38 USDMarket closedtoday -0.11%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets